| UHC UMR Medical and Drug | Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Transcatheter Procedures for Heart Valve Conditions – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Umbilical Cord Blood Harvesting and Storage for Future Use – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Ustekinumab – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Denosumab – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | FDA Cleared or Approved Companion Diagnostic Testing – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Provider Administered Drugs – Preferred Products – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Sodium Hyaluronate – Commercial Medical Benefit Drug Policy | 2026-07-01 |